Dobrin Draganov, PharmD. PhD.
Associate Vice President Translational Immuno-Oncology and Technology Development
Dr. Draganov is an accomplished scientist with more than 16 years of experience in the fields of cancer immunology and immunotherapy. He holds a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Immunology from Harvard University. Dr. Draganov did his doctoral thesis work at the Dana-Farber Cancer Institute, and Harvard Medical School, where he worked on designing new approaches to augment the therapeutic potential of GM-CSF-secreting whole tumor cell-based vaccines, also known as GVAX.
Dr. Draganov completed his postdoctoral training at the Department of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, where his work was focused on novel strategies to utilize synergistic drug combinations and immunogenic tumor cell death in the design of fully integrated cancer immunotherapies. These studies led to a USA Patent Filing describing novel approaches to use repurposed drugs targeting purinergic signaling in the context of combinatorial cancer immunotherapy.
Dr. Draganov is the recipient of a Novartis Fellowship and the Salvador E. Luria Prize, MIT. He is also a member of the Society for Immunotherapy of Cancer and SITC Cancer Immune Responsiveness Task Force.